Analysis of real-world prescribing patterns for SGLT2 inhibitors and GLP-1 drugs reveals uptake trends, prescriber preferences, and gaps between guidelines and practice.
Key findingAnalysis of real-world prescribing patterns for SGLT2 inhibitors and GLP-1 drugs reveals uptake tren
What the researchers found
Analysis of real-world prescribing patterns for SGLT2 inhibitors and GLP-1 drugs reveals uptake trends, prescriber preferences, and gaps between guidelines and practice.
Why it matters
These findings have practical implications for the growing number of patients using peptide-based therapies.
The numbers in context
Retrospective analysis of electronic medical records from a tertiary care center evaluating guideline adherence for SGLT2i and GLP-1 RA prescribing.
How the study worked
Study methodology detailed in the full publication.
Who was studied
Older adults with type 2 diabetes and cardiovascular or kidney disease at a tertiary care center
What this study cannot tell us
Study limitations in the full publication.
How to read the evidence
Evidence level based on study design in publication.
When this study was published
Published in 2025.
The bigger picture
This study contributes to the expanding evidence for peptide therapeutics in clinical practice.
Questions still open
- What are the long-term implications?
- How do results compare to other evidence?
- What further research is needed?
Common questions
What does this mean for patients?
How reliable is this?
Read the original research
Real-World Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Older Adults with Type 2 Diabetes and Cardiometabolic Disease.
Pharmaceuticals (Basel, Switzerland), 19(1)
Citation
Alhomoud, Ibrahim S; Alamer, Khalid A. (2025). Real-World Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Older Adults with Type 2 Diabetes and Cardiometabolic Disease.. Pharmaceuticals (Basel, Switzerland), 19(1). https://doi.org/10.3390/ph19010009